Tag: Lorlatinib

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Lorlatinib

European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK ...

Added to Collection on: 2022-01-30 10:05:42

Tags for this article:

Chemical compounds
Organic compounds
Aromatic compounds
Breakthrough therapy
Tyrosine kinase receptors
Lung cancer
Piperidines
Orphan drugs
ALK inhibitor
Anaplastic lymphoma kinase
Ceritinib
Lorlatinib
XALKORI
I Pfizer Inc.

Click the tags to see associated articles and topics

View Article Details
The Zacks Analyst Blog Highlights: AbbVie, Merck, Eli Lilly, Novartis and Pfizer - Entrepreneur

Added to Collection on: 2022-02-08 01:05:12

Tags for this article:

Life Sciences
Health sciences
Health care
Pfizer
ALK inhibitor
Pharmaceutical industry
AbbVie
Eli Lilly and Company
Lorlatinib
Securities research
Anaplastic lymphoma kinase
Angi Inc.

Click the tags to see associated articles and topics

View Article Details
Pfizer's Lorbrena shows PFS improvement in Phase III lung cancer trial

Added to Collection on: 2022-04-11 14:12:56

Tags for this article:

Chemical compounds
Organic compounds
Aromatic compounds
Lung cancer
Tyrosine kinase receptors
Piperidines
ALK inhibitor
Orphan drugs
Anaplastic lymphoma kinase
Crizotinib
Lorlatinib
Non-small-cell lung carcinoma
XALKORI
pfizer global

Click the tags to see associated articles and topics

View Article Details
Pfizer: Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY ...

Added to Collection on: 2022-09-19 07:24:41

Tags for this article:

Health
Articles
Committee for Medicinal Products for Human Use
European Medicines Agency
CHMP
Pfizer
Marketing authorization
Ravulizumab
Lorlatinib
BioNTech SE
Pfizer Inc.

Click the tags to see associated articles and topics

View Article Details
Biotech Co. Achieves High ORRs in Ph. 1 NSCLC Trial - Streetwise Reports

Added to Collection on: 2022-10-28 20:51:56

Tags for this article:

Chemical compounds
Tyrosine kinase receptors
Enzymes
ROS1
Aromatic compounds
Lorlatinib
Anaplastic lymphoma kinase
Non-small-cell lung carcinoma
Protein kinase inhibitor
Tyrosine-kinase inhibitor
Tyrosine kinase
Targeted therapy
Nuvalent Inc.

Click the tags to see associated articles and topics

View Article Details
Lorlatinib Market by Product Type (Tables 25mg, Tables 100mg), Application (Squamous ...

Added to Collection on: 2022-11-19 19:14:55

Tags for this article:

Business
Articles
Lorlatinib
Pyridines
Pyrroles
Market research
Economy
Marketing strategy
Market share
Market analysis
Market segmentation
Market
Consulting Private Limited.

Click the tags to see associated articles and topics

View Article Details
Lorlatinib Market Brief Analysis By Top Leading Companies | Pfizer - Digital Journal

Added to Collection on: 2022-12-20 14:31:59

Tags for this article:

Protein kinase inhibitors
Business
Lorlatinib
Pyridines
Pyrroles
Articles
Economy
Market analysis
Market research
Market segmentation
Compound annual growth rate
Marketing

Click the tags to see associated articles and topics

View Article Details
Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC: 5-Year Outcomes From Phase III ...

Added to Collection on: 2024-08-08 15:58:08

Tags for this article:

Fluoroarenes
Pyrazoles
Lung cancer
Tyrosine kinase receptors
CYP3A4 inhibitors
Lorlatinib
Crizotinib
Brain metastasis
Anaplastic lymphoma kinase
Non-small-cell lung cancer
Survival rate
Protein kinase inhibitor
Benjamin J. Solomon

Click the tags to see associated articles and topics

View Article Details
RUFY1-RET fusion identified as mechanism of resistance to lorlatinib in lung cancer

Added to Collection on: 2025-02-06 17:22:11

Tags for this article:

Tyrosine kinase receptors
Lung cancer
ROS1
Pyrazoles
Lorlatinib
Non-small-cell lung cancer
RET proto-oncogene
Cancer
Vanderbilt University School of Medicine

Click the tags to see associated articles and topics

View Article Details
Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management - OncLive

Added to Collection on: 2025-02-21 21:19:48

Tags for this article:

Pyrazoles
Orphan drugs
Lung cancer
Tyrosine kinase receptors
Antineoplastic drugs
Lorlatinib
ALK inhibitor
Crizotinib
Anaplastic lymphoma kinase
Non-small-cell lung cancer
ALK positive lung cancer
ROS1
Alectinib

Click the tags to see associated articles and topics

View Article Details